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Summary. Because the relationship between factor XII
deficiency and venous thrombosis is unclear and study
results seem contradictory, we undertook a population-
based case-control study.
Among 350 unselected patients younger than 70 years,
with a first, objectively conflrmed, episode of deep-vein
thrombosis and without underlying malignant disease we
detected a 6% frequency (21/350 patients) of factor XII
deficiency (activity level <57%). Among 350 healthy
control subjects, matched for age and sex, the frequency
was 5% (18 subjects). Thus there is no increase in
prevalence of factor XII deficiency among thrombosis
patients and no increase in thrombosis risk for subjects
with low factor XII levels (matched odds ratio 1-2 (95% CI
0-6-2-4)). In addition, there was no relation between strata
of factor XII levels and thrombosis risk. In conclusion, we do
not consider factor XII to be a determinant of deep-vein
thrombosis.
Keywords: clotting factor XII, Hageman factor, venous
thrombosis, case-control study.
Clotting factor XII (Hageman's factor) is involved in the
initiation of the intrinsic coagulation pathway and in
flbrinolysis (Kaplan & Silverberg, 1987). Theoretically,
deflciencies of factor XII may result in reduced coagulation
(bleeding risk) or reduced fibrinolytic activity (thrombosis
risk). There is a general consensus that factor XII deficiency
usually does not result in a haemorrhagic diathesis and only
exceptionally has a mild bleeding tendency been reported in
subjects with severe factor XII deficiency (Haanen et al,
1960; Didisheim, 1962; Ikkala et al, 1971). Its relationship
with overt venous thrombosis is still unclear. Some
investigators have reported high prevalences of factor XII
deficiency in patients with (recurrent) arterial and venous
thrombosis (Mannhalter et al, 1987; Halbmayer et al, 1992).
However, von Känel et al (1992) found no significant dif-
ferences in factor XII levels between thrombophilic patients
and control subjects, and subnormal factor XII values were
found equally frequent in patients and control subjects.
To further elucidate these obviously contradictory results,
we have investigated 350 unselected patients, aged less than
70, with a first, objectively confirmed, episode of deep-vein
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thrombosis and without underlying malignant disease, and
compared the plasma levels of factor XII with that of
matched healthy control subjects. This work was performed
äs part of an ongoing population-based case-control study
on hereditary venous thrombosis: the Leiden Thrombophilia
Study (LETS).
MATERIALS AND METHODS
Included were the first 350 patient-control pairs of the
larger study. The selection procedures for patients and
control subjects have been described in detail previously
(Koster et al, 1993). Briefly, consecutive patients, younger
than 70 years, who were referred for anticoagulant
treatment after a first, objectively confirmed, episode of
deep vein thrombosis that occurred between l January 1988
and 31 December 1992 were selected from the files of the
anticoagulation clinics in Leiden, Amsterdam and Rotter-
dam. For each patient we had one healthy control who
matched for age and sex.
The median time between the occurrence of the deep-vein
thrombosis and venepuncture for this study was 18 (ränge
6-48) months. Factor XII coagulant activity (FXII: C) was
measured by one-stage clotting assay using factor XII
deficient plasma and Automated APTT (Organon Teknica,
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Durham, U.S.A.) on an Electra lOOOc (MLA, Pleasantville,
U.S.A.).
A refereoce ränge for factor XII was derived from the
350 healthy control subjects. After natural logarithmic
transformation of the data and exclusion of two subjects
with values below three Standard deviations (SD) of the
mean, the lower limit of the normal factor XII distribution
was 57% (mean — 1-96 SD). We calculated crude matched
odds ratios äs estimates of the relative risk by simple cross
tabulation. We used Miettinen's test-based 95% confldence
limit. Since plasma factor XII has a continuum of values
instead of binary outcomes, we calculated matched odds
ratios, äs estimates of the relative risk, over several factor XII
strata, with 95% confldence limits.
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Table I. Thrombosis risk for strata of factor ΧΠ.
Factor XII activity (%) Patients Controls Odds ratio (95% CI)
MOO
60-100
30-60
<30
198
129
21
2
190
138
20
2
1*
0-9 (0-7-1-2)
1-0 (0-5-2-0)
1-0 (0-1-7-0)
* Reference category.
Table I gives the odds ratios for the strata of factor XII
levels. It shows no relation between the risk of thrombosis
and levels of factor XII, even for levels below 30% of normal.
RESULTS
The male/female ratio among patients and controls was
1/1-5 and mean age was 46 years (ränge 17-70 patients,
17-73 controls).
Three patients had an initially prolonged APTT consistent
with a lupus anticoagulant. Only one of them had a lower
factor XII level (32%).
The mean (ränge) factor XII coagulant activity was
104% (19-186) for the patients and likewise for the
controls (18-191).
Fig l shows that we found approximately the same
number of individuals with low levels in patients and
controls, regardless of the cut-off point used. If we apply our
lower limit of normal (factor XII activity of 57%), 21 (6%)
patients and 18 (5%) controls had low factor XII levels.
There were 33 discordant patient-control pairs, in 18 of
which the patients had low factor XII level and the control
subjects did not, thus resulting in a matched odds ratio of 1-2
(95% CI 0-6-2-4), i.e. no increase in risk of thrombosis
associated with low factor XII levels.
CONCLUSION
The flnding of a similar 5-6% prevalence of reduced factor
XII levels in 350 unselected patients, with a flrst, objectively
diagnosed, episode of venous thrombosis, and in healthy
age- and sex-matched controls, leads to the conclusion that
reduced factor XII levels are fairly common and that these
low levels do not represent an increased risk of deep-vein
thrombosis.
We did not find a subject with a homozygous or double
heterozygous factor XII deflciency (FXII < 1%). Therefore our
results only apply to heterozygous subjects or to individuals
with lowered levels. Since factor XII is only a weak
plasminogen activator and because there is still no
convincing evidence to support a causal relation between
thromboembolism and abnormalities of the flbrinolytic
System (Preston & Briet, 1993), one is tempted to theorize
that homozygous factor XII deflciency will also prove not to
be a predisposing cause of venous thrombosis. Therefore it
might be that John Hageman's pulmonary embolism cannot
be ascribed to his factor XII deflciency, but was more
probably due to his fractured hemipelvis and subsequent
bedrest (Ratnoff et al, 1968).
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Fig 1. Factor XII activity levels of thrombosis patients and
controls.
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